CureVac’s stock is up 6% as it begins regulatory process for its COVID-19 vaccine in the E.U.

Shares of CureVac CVAC, +2.08% gained 6.0% in premarket trading on Friday after the company said it started a rolling submission for its experimental mRNA-based COVID-19 vaccine in the European Union. The vaccine is currently being tested in a Phase 3 clinical trial in Europe and Latin America. CureVac’s stock has soared 64.4% over the past three months, while the S&P 500 SPX, +0.47% is up 9.6%.

View Article Origin Here